New Treatment Perspectives in Eating Disorders: the Efficacy of Non-invasive Brain-directed Treatment

NCT ID: NCT02382497

Last Updated: 2021-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Study Completion Date

2023-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study grounds on the possible role of hemispheric lateralization in Eating disorders (ED): specifically, hyperactivity of the right frontal regions in Anorexia Nervosa (AN), and hypoactivity of the right frontal regions in Binge Eating Disorder (BED) and food craving behaviors.

Therefore, the investigators hypothesized that active excitatory tDCS over left prefrontal cortex (PFC) (Anode left/cathode right) may aid in altering/resetting inter-hemispheric balance in AN patients, re-establish control over eating behaviors. On the contrary, active excitatory tDCS over right PFC (Anode right/cathode left) may aid in altering/resetting inter-hemispheric balance in BED patients and people with frequent food cravings, decreasing cravings/appetite binge eating behaviors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study design is randomized stratified, double blind, add-on, placebo-controlled.

A group of children and adolescents with AN will be selected and randomly assigned to two different conditions: treatment "as usual" plus experimental treatment (active tDCS); treatment "as usual" plus placebo treatment (sham tDCS).

Similarly, a group of children and adolescents with Over-weight/Obesity (OW/OB) and BED will be selected and assigned with randomized stratified sampling to the following conditions: treatment "as usual" plus experimental treatment (active tDCS); treatment "as usual" plus placebo treatment (sham tDCS).

In this project, the investigators will work to understand whether a brain-based treatment, with the use of tDCS, can improve the outcome of patients with eating disorders.

The investigators will test whether tDCS treatment produces improvements in under-eating and over-eating diseases, such us AN and OW/OB with BED and food craving.

Our overarching goal is to provide a scientific foundation for devising new rehabilitation strategies in ED.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eating Disorders Binge Eating Disorder Anorexia Nervosa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AN Active tDCS

Treatment "as usual" plus experimental treatment

Group Type EXPERIMENTAL

AN Active tDCS

Intervention Type DEVICE

The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.

tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.

The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.

Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.

AN Sham tDCS

Treatment "as usual" plus placebo treatment

Group Type SHAM_COMPARATOR

AN Sham tDCS

Intervention Type DEVICE

The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.

BED Active tDCS

Treatment "as usual" plus experimental treatment

Group Type EXPERIMENTAL

BED Active tDCS

Intervention Type DEVICE

The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.

tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.

For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.

Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.

BED Sham tDCS

Treatment "as usual" plus placebo treatment

Group Type SHAM_COMPARATOR

BED Sham tDCS

Intervention Type DEVICE

The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AN Active tDCS

The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.

tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.

The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.

Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.

Intervention Type DEVICE

AN Sham tDCS

The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.

Intervention Type DEVICE

BED Active tDCS

The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.

tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.

For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.

Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.

Intervention Type DEVICE

BED Sham tDCS

The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Brain Stim Brain Stim Sham Brain Stim Brain Stim

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Under-weight (BMI less than 5th percentile)1 with Clinical diagnosis of AN as described in the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
* Over-weight/Obesity (OW/OB) (BMI above the 85th percentile)1 with diagnosis of BED, or with food craving behaviors
* Ability to give informed consent under parents' surveillance and guidance

Exclusion Criteria

* Having a comorbidity with an important medical condition;
* Having neurological diseases
* Having Epilepsy o family history of epilepsy
* Pregnant or planning to become pregnant;
* Suicide risk;
* Receiving counseling or psychological therapies during the study;
* Receiving a treatment for an eating disorder in the previous three months before the baseline screening visit.
Minimum Eligible Age

10 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mariella Enoc

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mariella Enoc

Responsible of the Child Neuropsychiatry Unit

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stefano Vicari

Role: STUDY_CHAIR

Bambino Gesù Hospital and Research Institute

Floriana Costanzo

Role: PRINCIPAL_INVESTIGATOR

Bambino Gesù Hospital and Research Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bambino Gesù Hospital and Research Institute

Rome, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Floriana Costanzo

Role: CONTACT

Phone: 0668597091

Email: [email protected]

Valeria Zanna

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chiara Mennini

Role: primary

Rita Alparone

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. Int J Neuropsychopharmacol. 2011 Sep;14(8):1133-45. doi: 10.1017/S1461145710001690. Epub 2011 Feb 15.

Reference Type BACKGROUND
PMID: 21320389 (View on PubMed)

Costanzo F, Menghini D, Maritato A, Castiglioni MC, Mereu A, Varuzza C, Zanna V, Vicari S. New Treatment Perspectives in Adolescents With Anorexia Nervosa: The Efficacy of Non-invasive Brain-Directed Treatment. Front Behav Neurosci. 2018 Jul 20;12:133. doi: 10.3389/fnbeh.2018.00133. eCollection 2018.

Reference Type RESULT
PMID: 30083095 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

763_OPBG_2014

Identifier Type: -

Identifier Source: org_study_id